108 related articles for article (PubMed ID: 35998844)
1. High-glucose-induced hyperosmolar stress sensitizes HepG2 cell lines to sorafenib.
Esawie M; L Louka M; Hasanin AH; El-Kholy AA; Said Ali H
Gene; 2022 Nov; 844():146828. PubMed ID: 35998844
[TBL] [Abstract][Full Text] [Related]
2. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
3. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
4. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
[TBL] [Abstract][Full Text] [Related]
5. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
[TBL] [Abstract][Full Text] [Related]
6. Long non‑coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR‑675.
Xu Y; Liu Y; Li Z; Li H; Li X; Yan L; Mao J; Shen J; Chen W; Xue F
Oncol Rep; 2020 Jul; 44(1):165-173. PubMed ID: 32627034
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKα/NF-κB pathway.
Ji DG; Guan LY; Luo X; Ma F; Yang B; Liu HY
Biochem Biophys Res Commun; 2018 Jun; 501(1):33-40. PubMed ID: 29702091
[TBL] [Abstract][Full Text] [Related]
8. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
9. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR
BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
13. The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.
Ebrahim HM; El-Rouby MN; Morsy ME; Said MM; Ezz MK
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3369-3376. PubMed ID: 31759361
[TBL] [Abstract][Full Text] [Related]
14. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
[TBL] [Abstract][Full Text] [Related]
15. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
Zhang Z; He CZ; Qin YQ; Liao JJ; Huang ST; Mo S; Li HM; Lin JY
Aging (Albany NY); 2020 Nov; 12(23):24255-24269. PubMed ID: 33234725
[TBL] [Abstract][Full Text] [Related]
16. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
17. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
18. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
19. Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment.
Cheng CC; Chao WT; Liao CC; Tseng YH; Lai YC; Lai YS; Hsu YH; Liu YH
Cell Adh Migr; 2018 Jan; 12(1):19-27. PubMed ID: 28276928
[TBL] [Abstract][Full Text] [Related]
20. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]